Literature DB >> 30234458

In Vitro Radiobiological Advantages of Hypofractionation Compared with Conventional Fractionation: Early-Passage NSCLC Cells are Less Aggressive after Hypofractionation.

Haibo Zhang1,2, Chao Wan1, Jing Huang1, Chensu Yang1, You Qin1, Yanwei Lu1, Jia Ma1, Bian Wu1, Shuangbing Xu1, Gang Wu1, Kunyu Yang1.   

Abstract

Hypofractionated radiotherapy is a new and highly effective mode of radiation therapy. For this study we used biologically equivalent dose (BED), the dose required to give the same log cell kill as the schedule being studied. BED has been widely accepted to transform its dose to conventionally fractionated ones. However, actual differential effects beyond the clone-forming ability between hypofractionation and conventional radiation treatment remain unknown. We hypothesize that hypofractionation has some advantages over conventional treatment in in vitro radiobiology, excluding influences of the tumor microenvironment in angiogenesis and potential immune-stimulatory effects. For this study, two non-small cell lung cancer (NSCLC) cell lines with different α/β values were chosen: A549 (α/β = 12.4) and H460 (α/β = 2.95). We designed the following two fractionation regimens with equal BED: A549-HRT (10 Gy/1 fraction) and A549-CRT (16 Gy/8 fractions) as well as H460-HRT (10 Gy/1 fraction) and H460-CRT (26 Gy/13 fractions). After irradiation, we performed cell counting, MTT assay, flow cytometry analysis of apoptosis and cell cycle, immunocytofluorescence of γ-H2AX and Hoechst 33258, and senescence-associated β-galactosidase assay to identify differential effects. Glucose consumption and lactic acid production per cell were tested using glucose and lactate assays. Two weeks postirradiation, we collected early-passage cells of the colony cells after both conventional and fractionated irradiations for further investigation. Then, we used the side population (SP) assay, cell-counting assay and Transwell assay to test the proliferation and invasion capability, the MTT assay to identify the drug resistance of cisplatin, pemetrexed and docetaxel, the Western blot assay to test the stem cell-related proteins of NANOG, CD133, OCT4, SOX2, BMI1 and KLF4. After irradiation, the total cell count and cell viability in both cell lines gradually decreased in a similar manner. However, more senescent, necrotic cells and apoptotic cells were found in the conventionally-treated cells at an early time point postirradiation. Contrarily, a higher percentage of G2/M cell cycle arrest and more γ-H2AX foci were found in the cell lines that received hypofractionated treatment. Glucose consumption and lactic acid production per cell were lower in the cell lines that received hypofractionated irradiation. Early-passage cells in the conventional-treated cell line showed more SP cells with higher expressions of NANOG, OCT4 and BMI1 proteins. Early-passage cells in the conventional-treated cell line also revealed higher proliferative ability, drug resistance and invasion ability. Although we detected some radiobiological differences between the two fractionation treatments, there was no obvious advantage for hypofractionation in the early days postirradiation. However, there were some advantages for hypofractionation compared to conventional treatment in early-passage cells in vitro, which may partially contribute to its clinical advantages. Moreover, the damage to healthy tissue should also be addressed to fully elucidate the implications of radiotherapy addressed in this work.

Entities:  

Mesh:

Year:  2018        PMID: 30234458     DOI: 10.1667/RR14951.1

Source DB:  PubMed          Journal:  Radiat Res        ISSN: 0033-7587            Impact factor:   2.841


  7 in total

1.  Stereotactic Body Radiotherapy and Conventional Radiotherapy Induce Cytoskeleton Extension and Enlargement of Cell Morphology in Non-Small Cell Lung Cancer.

Authors:  Xiao Wang; Yanwei Lu; Zhiquan Qin; Haiwei Guo; Wenjuan Chen; Ting Ding; Jianming Tang; Haibo Zhang
Journal:  Dose Response       Date:  2021-12-17       Impact factor: 2.658

2.  Relationship between the invasion of lymphocytes and cytokines in the tumor microenvironment and the interval after single brachytherapy hypofractionated radiotherapy and conventional fractionation radiotherapy in non-small cell lung Cancer.

Authors:  Lin Li; Hong Cheng Yue; Yun Wei Han; Wei Liu; Liang Geng Xiong; Jian Wen Zhang
Journal:  BMC Cancer       Date:  2020-09-17       Impact factor: 4.430

3.  HIF1α/HIF2α-Sox2/Klf4 promotes the malignant progression of glioblastoma via the EGFR-PI3K/AKT signalling pathway with positive feedback under hypoxia.

Authors:  Pan Wang; Lu Zhao; Nan Wu; Bin Liao; Sheng Gong; Shuanglong Xiong; Junwei Wang; Dewei Zou; Jinyu Pan; Yangmin Deng; Qian Yan
Journal:  Cell Death Dis       Date:  2021-03-24       Impact factor: 8.469

4.  A Positive Feedback Loop of Long Noncoding RNA LINC00152 and KLF5 Facilitates Breast Cancer Growth.

Authors:  Qiang Li; Xiao Wang; Liheng Zhou; Mingyun Jiang; Guansheng Zhong; Shuguang Xu; Minjun Zhang; Yigan Zhang; Xiaodong Liang; Lei Zhang; Jianming Tang; Haibo Zhang
Journal:  Front Oncol       Date:  2021-03-26       Impact factor: 6.244

5.  The RNA-binding protein La/SSB associates with radiation-induced DNA double-strand breaks in lung cancer cell lines.

Authors:  Alexander H Staudacher; Yanrui Li; Vasilios Liapis; Michael P Brown
Journal:  Cancer Rep (Hoboken)       Date:  2021-10-12

6.  Challenges and Contradictions of Metal Nano-Particle Applications for Radio-Sensitivity Enhancement in Cancer Therapy.

Authors:  Eva Pagáčová; Lenka Štefančíková; Franz Schmidt-Kaler; Georg Hildenbrand; Tomáš Vičar; Daniel Depeš; Jin-Ho Lee; Felix Bestvater; Sandrine Lacombe; Erika Porcel; Stéphane Roux; Frederik Wenz; Olga Kopečná; Iva Falková; Michael Hausmann; Martin Falk
Journal:  Int J Mol Sci       Date:  2019-01-30       Impact factor: 5.923

7.  Hypo-fractionation radiotherapy normalizes tumor vasculature in non-small cell lung cancer xenografts through the p-STAT3/HIF-1 alpha signaling pathway.

Authors:  Fan Tong; Chun-Jin Xiong; Chun-Hua Wei; Ye Wang; Zhi-Wen Liang; Hui Lu; Hui-Jiao Pan; Ji-Hua Dong; Xue-Feng Zheng; Gang Wu; Xiao-Rong Dong
Journal:  Ther Adv Med Oncol       Date:  2020-10-29       Impact factor: 8.168

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.